Figures
Abstract
Our recent publication showed that a small bioactive pigment epithelium derived factor (PEDF) peptide (P78-PEDF) prevents the development of diabetic nephropathy (DN). However, its effects on the progression of established DN were not clear. Therefore, the purpose of this study was to determine the effect of P78-PEDF in the progression of DN and to compare the effects of P78-PEDF and an ACE inhibitor (ACEi), a standard of care in DN. Experiments were conducted in Ins2Akita mice treated with P78-PEDF or captopril starting at 6 wks of age for 12 wks (early treatment) or starting at 12 wks of age for 6 wks (late treatment). We first established the optimal dose of the P78-PEDF peptide to ameliorate DN in Ins2Akita mouse for a 6 wk study period and found that the peptide was effective at 0.1- 0.5 µg/g/day. We next showed that early or late treatment with P78-PEDF resulted in protection from DN as indicated by reduced albuminuria, kidney macrophage recruitment, histological changes, inflammatory cytokines and fibrotic markers (kidney TNF-α, fibronectin, VEGFA and EGFR), and restored nephrin expression compared with vehicle-treated Ins2Akita mice. Interestingly, only early but not late treatment with captopril was as effective as P78-PEDF in reducing most DN complications, despite its lack of effect on nephrin, VEGFA and EGFR expression. These findings highlight the importance of P78-PEDF peptide as a potential therapeutic modality in both the development and progression of diabetic renal injury.
Citation: Awad AS, You H, Gao T, Gvritishvili A, Cooper TK, Tombran-Tink J (2015) Delayed Treatment with a Small Pigment Epithelium Derived Factor (PEDF) Peptide Prevents the Progression of Diabetic Renal Injury. PLoS ONE 10(7): e0133777. https://doi.org/10.1371/journal.pone.0133777
Editor: David Long, UCL Institute of Child Health, UNITED KINGDOM
Received: March 18, 2015; Accepted: July 1, 2015; Published: July 24, 2015
Copyright: © 2015 Awad et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: This study was supported by NIH Grants DK094930 and DK094930S1, and grants from Novo Nordisk and JDRF. The PI only received grant money from Novo Nordisk to conduct this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: There are no competing interests, employment, consultancy, patents, products in development, marketed products, etc from Novo Nordisk. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
Introduction
Diabetes mellitus (DM) is a global health problem with marked morbidity and mortality and is often complicated by micro- and macrovascular involvement, which contributes to damage to one or more target organs. Diabetic nephropathy (DN) is the most severe complication of DM worldwide and is the leading cause of end stage kidney disease, responsible for over 43% of all cases in the US and this number is likely to increase unabated [1]. Current therapies including blood pressure and glucose control and other life style changes have been only modestly successful in delaying the progression of renal failure [2]. Angiotensin converting enzyme (ACE) inhibitors (ACEi) are recognized as the standard of care in DN. However, this therapy does not result in full reversal or even fully prevent the deterioration of renal function [3]. Thus, it is important to identify new pharmacotherapeutics that will prevent or slow down the development and progression of diabetic kidney disease.
Inflammation, angiogenesis, and oxidative injury are central pathophysiological mechanisms that contribute to diabetes and DN. Pigment epithelium derived factor (PEDF) is a multifunctional, pleiotropic, secretory protein with anti-angiogenic, anti-oxidative and anti-inflammatory properties [4, 5]. PEDF plays an important role in early renal postnatal development [6]. PEDF knockout mice are both obese and diabetic [7]. PEDF acts via multiple high affinity ligands and cell receptors, although the mechanisms are not clear. There is convincing evidence that PEDF’s role in obesity and diabetes is mediated, in part, through binding to adipose triglyceride lipase (ATGL), a receptor that is essential to maintaining lipid and glucose homeostasis [8, 9]. Clinical studies have demonstrated the importance and correlation between serum PEDF levels with metabolic syndrome [10], insulin resistance [11], and renal failure [12]. In addition, a therapeutic role for PEDF in diabetic retinopathy has been clearly established [5, 13, 14]. In a recent cross sectional study, urinary PEDF was significantly increased in diabetic patients [15]. Since PEDF is a 50 kDa protein, its utility as a therapeutic agent may be limited. Recent evidence suggests that fragments of PEDF are bioactive. In particular, a 44 amino acid (AA 78–121; P78-PEDF) peptide shows excellent bioactivity in several reports [16, 17]. We have recently shown that P78-PEDF prevents the development of diabetic renal injury (primary prevention) [18], but whether P78-PEDF may also reduce the progression of DN (secondary prevention) is not clear and was the focus of this study, along with determining the optimal dose required for these activities. In addition, we compared P78-PEDF treatment to captopril (an ACEi), the standard of care for both primary and secondary prevention of DN.
Our data showed that P78-PEDF peptide treatment not only prevented the development but also progression of DN in the Ins2Akita mouse model of diabetes as indicated by reduced albuminuria, decreased kidney macrophage recruitment and inflammatory cytokines (kidney TNF-α, fibronectin, VEGFA and epidermal growth factor receptor (EGFR)), reduced histological changes, and increased nephrin expression compared to vehicle-treated Ins2Akita mice. In addition, P78-PEDF peptide but not captopril restored nephrin and reduced kidney VEGFA and EGFR expressions. These results provide evidence for use of P78-PEDF as a novel therapeutic intervention in the development and progression of diabetic renal injury.
Materials and Methods
Diabetic mouse models
This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The study was approved by the Penn State University College of Medicine Institutional Animal Care and Use Committee. Experiments were conducted in male D2.B6-Ins2Akita/MatbJ and their wild type (WT) littermate mice (DBA/2J background; The Jackson Laboratory, stock number 007562) starting at 6 wks of age (~3 wks of diabetes). Ins2Akita mice, recommended by the Animal Models of Diabetes Complications Consortium (AMDCC) as a model of DN [19, 20], develop hyperglycemia at 3 wks of age. Mice with blood glucose levels > 350 mg/dl were considered diabetic. Mice were provided ad lib access to food and water. Urine collections were obtained by housing mice in metabolic cages. At the end of experiments, mice were euthanized by intraperitoneal injection of 100mg/kg ketamine (Henry Schein Animal Health, Dublin, OH) and 10mg/kg xylazine (Lloyd Laboratories Inc, Shenandoah, Iowa), kidneys were removed and plasma was collected for further studies.
Drug delivery
We first established a dose response for P78-PEDF (0.01, 0.05, 0.1, 0.5 µg/g/day), a small PEDF peptide [16–18, 21] or vehicle (PBS) by continuous subcutaneous infusion beginning at 6 wks of age until 12 wks of age. We next used P78-PEDF at a dose of 0.3 μg/g/day, captopril (24 mg/L daily in drinking water; Sigma), or vehicle (PBS) via osmotic minipump starting at 6 wks (early treatment) or 12 wks (late treatment) of age until 18 wks of age.
Blood pressure measurement
Systolic blood pressure was measured using the Coda blood pressure system (Kent Scientific Corp, Torrington, Connecticut) as previously described [18, 22–24]. Mice were habituated to the blood pressure measurement for 5 days before the experiment and then were allowed to rest quietly for 15 minutes at room temperature. All measurements were performed at the same time for each group to avoid any diurnal variations.
Histology and immunohistochemistry
Mouse kidney tissues were fixed in 4% paraformaldehyde and embedded in paraffin. Periodic acid Schiff (PAS) staining was performed on 3 μm sections. All glomeruli (between 50–100 glomeruli) in a single transverse section for each mouse were examined under a microscope at 400× total magnification and scored individually in a blinded manner and then averaged. Semiquantitative scores (0–4+) were assigned based on blinded readings. Mesangial matrix expansion or sclerosis scoring was performed as we described previously [18, 22, 25–27]. Images were captured with an Olympus BX51 microscope and DP71 digital camera using cellSens Standard 1.12 image software. Images were obtained with 100× (oil) objective with a total magnification of 1000×. Immunohistochemistry for macrophages was performed using rat anti-mouse Mac-2 antibody (clone M3/38; Cedarlane, Burlington, NC) on paraffin sections as described previously [18, 25–27].
Quantitative reverse transcription polymerase chain reaction (qRT-PCR)
Total RNA was isolated from kidneys using Tri reagent (Molecular Research Center, Inc, Cincinnati, OH, USA) per manufacturer’s protocol. Single-strand cDNA was synthesized using iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA) for two-step qRT-PCR. Quantitative PCR was performed using Taqman gene expression assays (TNF-α: Mm00443260_g1, fibronectin: Mm01256744_m1, VEGFA: Mm01281449_m1, EGFR: Mm00433023_m1; GAPDH: Mm99999915_g1; Life Technologies, Grand Island, NY, USA) using a Bio-Rad CFX96 Real-Time System. Data were analyzed using Bio-Rad CFX Manager Software version 2.0 and relative expression quantified using the 2(-∆∆CT) equation after normalization to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as described previously [18, 22, 25, 26].
Western blot
Kidney tissues were homogenized in lysis solution (0.1% Triton X-100) supplemented with protease inhibitor cocktail tablets (Roche). BCA protein assay (Thermo Fisher Scientific) was used to determine protein concentration. Fifteen μg of kidney lysates were separated on a NuPAGE 4~12% Bis-Tris Gel (Invitrogen) and the separated proteins transferred onto a polyvinylidene difluoride membrane (Invitrogen). After blocking using 5% non-fat dry milk, membranes were incubated with primary antibody overnight at 4°C, followed by incubation with appropriate secondary antibody for 1 hour at room temperature. Membranes were probed with primary antibodies to nephrin (1:500; Fitzgerald Industries International, cat. no. 20R-NP002) or GAPDH (1:1000; Cell Signaling Technology, Inc., cat. no. 5174S). The secondary antibody used for detection of nephrin was anti-guinea pig IgG-HRP (1:2000; Fitzgerald Industries International, cat. no. 43R-1096). Membranes were developed using enhanced chemiluminescence solutions (Thermo Fisher Scientific) followed by exposure to X-ray film and densitometry performed using Image J (NIH, http://rsbweb.nih.gov/ij/index.html) as described [18, 22, 24].
Analytical methodology
Urine albumin was measured by ELISA using an Albuwell M kit (Exocell, Philadelphia, PA) [18, 22, 25, 27, 28]; and Body composition calculated using a LF90 Minispec Time Domain Nuclear Magnetic Resonance Spectrometer (Burker Optics, Billerica, MA) [18, 25, 27, 28].
Statistical analysis
Comparisons among groups were performed using the SPSS version 19.0 software (SPSS, Chicago, IL) program. Data are expressed as mean ± SEM. One-way ANOVA was used when more than two groups were compared, and significance of observed differences among the groups evaluated with a least significant difference post hoc test. Statistical significance was identified at p< 0.05.
Results
P78-PEDF reduces characteristics of DN in Ins2Akita mice in a dose-dependent manner
We first determined the optimal dose (0.01, 0.05, 0.1, 0.5 μg/g/day) for P78-PEDF in Ins2Akita mice for 6 wks, beginning at 6 wks of age. As shown in Table 1, Ins2Akita vehicle-treated mice had increased blood glucose level, decreased body weight, and reduced fluid composition compared to normal mice. Treatment with P78-PEDF did not reduce blood glucose levels or blood pressure at any dose used. We also measured urine albumin excretion (UAE) as an indicator of diabetic kidney injury. Vehicle-treated Ins2Akita mice had a significant increase in UAE (Fig 1) compared to non-diabetic mice at 12 wks of age. Albuminuria was significantly reduced in Ins2Akita mice treated with all doses of P78-PEDF at 12 wks of age compared to vehicle treated mice.
Ins2Akita mice were treated with vehicle or P78-PEDF peptide (0.01, 0.05, 0.1, 0.5 μg/g/day) via osmotic minipump for 6 wks. Urine was collected at 12 wks of age for measurement of UAE. Results are means ± SEM. *p<0.001 compared to normal; #p<0.05 compared to vehicle-treated Ins2Akita mice.
P78-PEDF decreases renal histological changes in Ins2Akita mice in a dose-dependent manner
PAS staining of kidney sections (Fig 2) revealed increased glomerular cellularity and mesangial expansion (p<0.001) at 12 wks of age in vehicle-treated Ins2Akita mice vs. normal. P78-PEDF treatment in Ins2Akita mice resulted in significantly reduced glomerular cellularity and mesangial expansion at a dose of 0.1 μg/g/day (p<0.001) and 0.5 μg/g/day (p<0.05) compared to vehicle-treated Ins2Akita mice.
Sections were stained with PAS and all glomeruli were graded individually at 400x magnification after 12 wks of age in normal (A), vehicle-treated Ins2Akita (B) and P78-PEDF peptide-treated (Dose: μg/g/day; 0.01: C, 0.05: D, 0.1: E, 0.5: F) Ins2Akita mice. Images were taken with 100x (oil) objective with a total magnification of 1000x. Images are representative of 10–13 mice in each group. G: PAS score. Results are means ± SEM. *p<0.001 compared to normal; #p<0.05, ##p<0.001 compared to vehicle-treated Ins2Akita mice.
P78-PEDF decreases macrophage recruitment in Ins2Akita mice in a dose-dependent manner
To determine whether P78-PEDF treatment is critical for kidney macrophage infiltration in DN, we examined the distribution and number of macrophages in the kidney by immunohistochemistry (Mac-2 positive macrophages) (Fig 3). The number of glomerular macrophages in normal mice was low but increased significantly in vehicle-treated Ins2Akita mice (p<0.01) at 12 wks of age. All doses of P78-PEDF treatment in Ins2Akita mice resulted in significantly reduced glomerular macrophage recruitment with an optimal dose of 0.5 μg/g/day (p<0.001) compared to vehicle-treated Ins2Akita mice. Given these results (Figs 1–3), we used a P78-PEDF peptide dose of 0.3 μg/g/day in all subsequent experiments.
Mac-2-positive macrophages (red arrows) in glomeruli were identified by immunohistochemical staining at 12 wks of age in normal (A), vehicle-treated Ins2Akita (B) and P78-PEDF peptide-treated (Dose: μg/g/day; 0.01: C, 0.05: D, 0.1: E, 0.5: F) Ins2Akita mice. Images are representative of 40 fields from 10–13 mice in each group. G: The number of macrophages/glomerulus. Results are means ± SEM. *p<0.01 compared to normal; #p<0.05, ##p<0.001 compared to vehicle-treated Ins2Akita mice.
Delayed treatment with P78-PEDF ameliorates the progression in DN of Ins2Akita mice
Once we determined the optimal dose of P78-PEDF in DN, we further assessed the direct contribution of P78-PEDF in the progression of DN. Ins2Akita mice were treated with P78-PEDF (0.3 μg/g/day), captopril (24 mg/L daily in drinking water), or vehicle via osmotic minipump starting at 6 wks of age until 18 wks of age (early treatment) or at 12 wks of age until 18 wks of age (late treatment). As shown in Table 2, Ins2Akita vehicle-treated mice had increased blood glucose level, decreased body weight, and reduced fluid composition compared to normal mice. Early or late treatment with either P78-PEDF or captopril did not reduce blood glucose levels or blood pressure. We next measured UAE as an indicator of diabetic kidney injury. Vehicle-treated Ins2Akita mice had a significant increase in UAE (Fig 4) compared to normal mice at 18 wks of age. Importantly, albuminuria was significantly reduced in Ins2Akita mice with either early or late P78-PEDF treatment at 18 wks of age compared to vehicle treated mice. Interestingly, only early but not late treatment with captopril significantly reduced albuminuria to a similar extent as early treatment with P78-PEDF.
Ins2Akita mice were treated with vehicle or P78-PEDF peptide (0.3 μg/g/day) via osmotic minipump or captopril (24 mg/L daily in drinking water; Sigma) starting at 6 wks (early treatment) or 12 wks (late treatment) of age. Urine was collected from each group of mice at 6, 12, and 18 wks of age for measurement of UAE. Results are means ± SEM. *p<0.05, **p<0.001, ***p<0.0001 compared to corresponding normal; #p<0.01 compared to corresponding vehicle-treated Ins2Akita mice.
Delayed treatment with P78-PEDF decreases renal histopathological changes in DN of Ins2Akita mice
PAS staining of kidney sections (Fig 5) revealed increased glomerular cellularity and mesangial expansion (p<0.001) at 18 wks of age in vehicle-treated Ins2Akita mice. Early or late treatment with P78-PEDF at 18 wks of age in Ins2Akita mice resulted in significantly reduced glomerular cellularity and mesangial expansion compared to vehicle-treated Ins2Akita mice. In contrast, only early but not late treatment with captopril was comparable to the same treatment with P78-PEDF in significantly reducing glomerular cellularity and mesangial expansion.
Sections were stained with PAS and all glomeruli were graded individually at 400x magnification after 18 wks of age in normal (A), vehicle-treated Ins2Akita (B), P78-PEDF peptide early treated (C), P78-PEDF peptide late treated (D), captopril early treated (E), or captopril late treated (F) Ins2Akita mice. Images were taken with 100x (oil) objective with a total magnification of 1000x. Images are representative of 7–13 mice in each group. G: PAS score. Results are means ± SEM. *p<0.01, **p<0.001 compared to normal; #p<0.01 compared to vehicle-treated Ins2Akita mice.
Delayed treatment with P78-PEDF decreases macrophage recruitment in DN of Ins2Akita mice
To determine the extent to which P78-PEDF treatment was effective in reducing progression of DN as it does in the development of DN by reducing kidney macrophage infiltration, we examined distribution and number of macrophages in the kidney by immunohistochemistry (Mac-2 positive macrophages) (Fig 6). The number of glomerular macrophages in normal mice was low and increased significantly in vehicle-treated Ins2Akita mice (p<0.01) at 18 wks of age. Early or late treatment with P78-PEDF at 18 wks of age in Ins2Akita mice resulted in significantly reduced glomerular macrophage recruitment compared to vehicle-treated Ins2Akita mice. In contrast, only early treatment with captopril was comparable to early treatment with P78-PEDF in significantly reducing glomerular macrophage recruitment. Late captopril treatment was less effective than late P78-PEDF treatment.
Mac-2-positive macrophages in glomeruli (red arrows) were identified by immunohistochemical staining at 18 wks of age in normal (A), vehicle-treated Ins2Akita (B), P78-PEDF peptide early treated (C), P78-PEDF peptide late treated (D), captopril early treated (E), or captopril late treated (F) Ins2Akita mice. Images are representative of 40 fields from 7–13 mice in each group. G: The number of macrophages/glomerulus. Results are means ± SEM. *p<0.01 compared to normal; #p<0.05 compared to vehicle-treated Ins2Akita mice.
Delayed treatment with P78-PEDF decreases inflammatory cytokines and fibrotic markers in DN of Ins2Akita mice
Increased inflammatory cytokines and fibrotic markers are major features of and important predictors of DN [18, 29, 30]. Therefore, we further assessed the anti-inflammatory and anti-fibrotic effects of P78-PEDF treatment in diabetic mice (Fig 7). Kidney TNF-α (Fig 7A), fibronectin (Fig 7B), VEGFA (Fig 7C), and EGFR (Fig 7D) mRNA expression were significantly increased in vehicle-treated Ins2Akita mice at 18 wks of age compared to normal mice. Both early and late treatments of Ins2Akita mice at 18 wks of age with P78-PEDF significantly reduced kidney TNF-α, fibronectin, VEGFA, and EGFR mRNA expression levels compared to vehicle-treated Ins2Akita mice. In contrast, only early but not late treatment with captopril significantly reduced kidney TNF-α mRNA expression without affecting kidney fibronectin, VEGFA or EGFR mRNA expression levels.
RT-PCR was performed on whole mouse kidney total RNA at 18 wks of age. TNF-α (A), fibronectin (B), VEGFA (C), and EGFR (D) mRNA expression were normalized with GAPDH. Results are means ± SEM. *p<0.05, **p<0.01 compared to normal; #p<0.05, ##p<0.01 compared to Ins2Akita+vehicle.
Delayed treatment with P78-PEDF prevents reduction in nephrin protein expression in Ins2Akita mice
Nephrin is a critical component protein in the glomerular slit diaphragm, which plays a pivotal role in maintaining kidney function. A decrease in nephrin expression is associated with albuminuria. As shown in Fig 8, nephrin protein expression was significantly reduced in vehicle-treated Ins2Akita mice at 18 wks of age compared to normal mice. Early treatment with P78-PEDF in Ins2Akita mice resulted in significantly increased nephrin protein expression compared to vehicle-treated Ins2Akita mice of the same age while late P78-PEDF treatment was not significantly different compared to normal mice. In contrast, neither early nor late treatment with captopril affected nephrin protein expression, which was comparable in levels to vehicle-treated Ins2Akita mice.
Kidney nephrin expression was detected using western blot at 18 wks of age. Quantification was performed by densitometry followed by normalization to GAPDH. Results are means ± SEM. *p<0.01, **p<0.01 compared to normal; #p<0.05 compared to vehicle-treated Ins2Akita mice; †p<0.05 compared to Ins2Akita mice treated with captopril early.
Discussion
Despite major efforts to understand the pathogenesis of DN, the disease still progresses in spite of current therapeutic measures, such as control of blood pressure and blood glucose levels and use of renin-angiotensin-aldosterone system inhibitors [2]. Identification of other DN targets may lead to more effective treatments or prevention of disease progression. Accumulating evidence suggests that PEDF is one such factor in developing treatments for diabetic renal injury. PEDF has well-established anti-angiogenic, anti-oxidative and anti-inflammatory actions in the eye [4, 5], yet its role in diabetic kidney injury is not completely clear. We have shown previously that P78-PEDF treatment confers kidney protection in preventing DN [18]; however that study was only focused on early stage (development) DN. Whether P78-PEDF treatment is also important in delaying the progression of DN was not clear. Understanding the role of P78-PEDF in treating (rather than preventing) DN will have clinical relevance. The current study shows that P78-PEDF prevents the development and progression of DN in the Ins2Akita mice, a well-established model of type-1 diabetes. This conclusion is based on its ability to reduce albuminuria, histopathological changes, kidney macrophage recruitment, inflammatory cytokines, and fibrotic markers associated with diabetes. Furthermore, both early and late treatment with P78-PEDF preserved expression of the podocyte structural protein nephrin during diabetes. These findings reveal an important role for P78-PEDF peptide and/or other PEDF peptides in the development and progression of DN. Thus, P78-PEDF is a potentially new therapeutic tool for treating diabetic patients.
The PEDF protein is expressed in several tissues and cell types including the postnatal kidney [6]. In addition, we have shown that PEDF is expressed in the kidney vasculature, interstitial spaces, glomeruli, medulla and tubular epithelial cells, and glomerular endothelial cells [18] and that the protein and mRNA levels were markedly reduced in diabetic mice [18] and rat kidney [31].
In this study, the renal protective effects of early or late treatment with P78-PEDF peptide correlate with a significant reduction in kidney macrophage infiltration. Infiltrating macrophages can release lysosomal enzymes, nitric oxide, reactive oxygen species, transforming growth factor-beta, vascular endothelial growth factor and cytokines such as TNF-α, interleukin-1 and interferon (IFN)-γ [32], which could play a pivotal role in the development and progression of DN. We have shown previously that early treatment with P78-PEDF peptide significantly reduced the increase in urinary TNF-α and kidney VEGFA protein levels [18]. The current study confirms these results and shows that early or late treatment with P78-PEDF significantly reduced kidney TNF-α, and VEGFA expressions. TNF-α is produced mainly by monocytes/macrophages and is associated with increasing vascular endothelial permeability in diabetes mellitus [33]. PEDF has been shown to counteract the effects of VEGF [34]. Increased VEGF can lead to glomerular hypertrophy and proteinuria [35], and thickening of glomerular basement membrane [36, 37]. Both early and late treatment with the P78-PEDF peptide also resulted in less mesangial expansion and glomerular hypercellularity in diabetes and was associated with reduced fibronectin mRNA expression, indicating a possible association between PEDF reduction in the diabetic kidney with initiation and/or progression of diabetic renal fibrosis.
Since ACEi is the gold standard for treating diabetic patients, every potential new therapy should be compared to it as standard of care. Our data show that early treatment with captopril, an ACEi, was almost as effective as early treatment with P78-PEDF in reducing albuminuria, kidney macrophages recruitment, and histopathological changes along with reduced kidney TNF-α expression. Early treatment with captopril however, lacks any effects on kidney VEGFA, fibronectin or nephrin expression levels. Interestingly, late treatment with captopril lacks any effect to ameliorate diabetic renal injury. Additional studies to investigate the role of combined P78-PEDF and captopril treatments will be needed in future study.
The mechanism by which P78-PEDF peptide mediates protection in DN is not completely known. We have shown previously, that P78-PEDF peptide may have a direct effect on podocytes [18]. Podocytes play a key role in the maintenance of the glomerular filtration barrier [38], and normal podocyte function is intimately linked to its complex cytoskeletal architecture. The effects of early or late treatment with P78-PEDF to restore nephrin protein expression further support this conclusion. In addition, our data show increased EGFR expression in vehicle-treated Ins2Akita mice at 18 wks of age. Both early and late treatments of Ins2Akita mice at 18 wks of age with P78-PEDF significantly reduced kidney EGFR expression levels compared to vehicle-treated Ins2Akita mice. EGFR is widely expressed and induced in the kidney [39, 40]. Inhibition of EGFR has been shown to prevent DN [41]. We also speculate that macrophage infiltration plays a major role in PEDF-mediated renal tissue protection in DN. This conclusion is based on our results using diabetic CD11b-DTR mice, in which human DTR expression is under the control of the CD11b promoter [18]. Our data show that macrophage depletion in diabetic CD11b-DTR mice using diphtheria toxins restored PEDF protein expression to normal levels (S1 Fig). Additional studies to investigate the direct interaction between macrophages and PEDF will be needed in future.
In conclusion, our study demonstrates that treatment with P78-PEDF not only prevents the development but also the progression of DN. Results of this study may ultimately lead to novel therapeutic interventions using P78-PEDF peptide in the treatment of diabetic kidney disease.
Supporting Information
S1 Fig. Macrophage depletion in diabetic CD11b-DTR mice restores PEDF protein expression to normal levels.
Male 6-wk-old B6.FVB-Tg(ITGAM-DTR/EGFP)34Lan/J (CD11b-DTR) mice (stock no. 006000, Jackson Laboratory, Bar Harbor, MN) were given multiple intraperitoneal injections of vehicle or STZ. A diphtheria toxin (DT) (List Biological Laboratories) was injected intraperitoneally at the dose of 25 ng/g body wt weekly for 6 wk after STZ injection [25]. Kidney tissues were homogenized in lysis solution as indicated in the Method section for western blot analysis of PEDF expression as we described previously [18]. Quantification was performed by densitometry followed by normalization to GAPDH. Results are means ± SEM for n = 4–5 mice in each group. *p<0.05 compared to diabetic CD11b-DTR mice treated with diphtheria toxins.
https://doi.org/10.1371/journal.pone.0133777.s001
(PDF)
Author Contributions
Conceived and designed the experiments: ASA JT. Performed the experiments: ASA HY TG AG TKC JT. Analyzed the data: ASA HY AG TKC JT. Contributed reagents/materials/analysis tools: ASA JT. Wrote the paper: ASA TKC JT.
References
- 1. Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010;8:29. Epub 2010/10/26. doi: 1478-7954-8-29 [pii] pmid:20969750; PubMed Central PMCID: PMC2984379.
- 2. Abdel-Rahman EM, Saadulla L, Reeves WB, Awad AS. Therapeutic modalities in diabetic nephropathy: standard and emerging approaches. J Gen Intern Med. 2012;27(4):458–68. Epub 2011/10/19. pmid:22005942; PubMed Central PMCID: PMC3304033.
- 3. Lovell HG. Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria. Cochrane Database Syst Rev. 2000;(2):CD002183. Epub 2000/05/05. doi: CD002183 [pii] pmid:10796871.
- 4. Tombran-Tink J, Barnstable CJ. Therapeutic prospects for PEDF: more than a promising angiogenesis inhibitor. Trends Mol Med. 2003;9(6):244–50. Epub 2003/06/28. doi: S1471491403000741 [pii]. pmid:12829012.
- 5. Tombran-Tink J. PEDF in angiogenic eye diseases. Curr Mol Med. 2010;10(3):267–78. Epub 2010/03/20. doi: CMM # 30 [pii]. pmid:20236057.
- 6. Pina AL, Kubitza M, Brawanski A, Tombran-Tink J, Kloth S. Expression of pigment-epithelium-derived factor during kidney development and aging. Cell Tissue Res. 2007;329(2):329–38. Epub 2007/05/15. pmid:17497179.
- 7. Gattu AK, Birkenfeld AL, Iwakiri Y, Jay S, Saltzman M, Doll J, et al. Pigment epithelium-derived factor (PEDF) suppresses IL-1beta-mediated c-Jun N-terminal kinase (JNK) activation to improve hepatocyte insulin signaling. Endocrinology. 2014;155(4):1373–85. Epub 2014/01/25. pmid:24456163.
- 8. Notari L, Baladron V, Aroca-Aguilar JD, Balko N, Heredia R, Meyer C, et al. Identification of a lipase-linked cell membrane receptor for pigment epithelium-derived factor. J Biol Chem. 2006;281(49):38022–37. Epub 2006/10/13. doi: M600353200 [pii] pmid:17032652.
- 9. Chung C, Doll JA, Gattu AK, Shugrue C, Cornwell M, Fitchev P, et al. Anti-angiogenic pigment epithelium-derived factor regulates hepatocyte triglyceride content through adipose triglyceride lipase (ATGL). J Hepatol. 2008;48(3):471–8. Epub 2008/01/15. doi: S0168-8278(07)00626-5 [pii] pmid:18191271.
- 10. Yamagishi S, Adachi H, Abe A, Yashiro T, Enomoto M, Furuki K, et al. Elevated serum levels of pigment epithelium-derived factor in the metabolic syndrome. J Clin Endocrinol Metab. 2006;91(6):2447–50. Epub 2006/03/09. doi: jc.2005-2654 [pii] pmid:16522692.
- 11. Nakamura K, Yamagishi S, Adachi H, Matsui T, Kurita Y, Imaizumi T. Serum levels of pigment epithelium-derived factor (PEDF) are an independent determinant of insulin resistance in patients with essential hypertension. Int J Cardiol. 2010;143(1):96–8. Epub 2008/12/17. doi: S0167-5273(08)01372-7 [pii] pmid:19073347.
- 12. Motomiya Y, Yamagishi S, Adachi H, Abe A. Increased serum concentrations of pigment epithelium-derived factor in patients with end-stage renal disease. Clin Chem. 2006;52(10):1970–1. Epub 2006/09/26. doi: 52/10/1970 [pii] pmid:16998120.
- 13. Liu Y, Leo LF, McGregor C, Grivitishvili A, Barnstable CJ, Tombran-Tink J. PEDF peptide eye drops reduce inflammation, cell death, and vascular leakage in diabetic retinopathy in the Ins2akita mice. Mol Med. 2012. Epub 2012/09/29. doi: molmed.2012.00008 [pii] pmid:23019073.
- 14. Tombran-Tink J. The neuroprotective and angiogenesis inhibitory serpin, PEDF: new insights into phylogeny, function, and signaling. Front Biosci. 2005;10:2131–49. Epub 2005/06/23. doi: 1686 [pii]. pmid:15970483.
- 15. Chen H, Zheng Z, Li R, Lu J, Bao Y, Ying X, et al. Urinary pigment epithelium-derived factor as a marker of diabetic nephropathy. Am J Nephrol. 2010;32(1):47–56. Epub 2010/06/05. doi: 000314326 [pii] pmid:20523035.
- 16. Liu Y, Leo LF, McGregor C, Grivitishvili A, Barnstable CJ, Tombran-Tink J. Pigment epithelium-derived factor (PEDF) peptide eye drops reduce inflammation, cell death and vascular leakage in diabetic retinopathy in Ins2(Akita) mice. Mol Med. 2012;18:1387–401. Epub 2012/09/29. doi: molmed.2012.00008 [pii] pmid:23019073; PubMed Central PMCID: PMC3533643.
- 17. Gvritishvili AG, Leung KW, Tombran-Tink J. Codon preference optimization increases heterologous PEDF expression. PLoS One. 2010;5(11):e15056. Epub 2010/12/15. pmid:21152082; PubMed Central PMCID: PMC2994832.
- 18. Awad AS, Gao T, Gvritishvili A, You H, Liu Y, Cooper TK, et al. Protective role of small pigment epithelium-derived factor (PEDF) peptide in diabetic renal injury. Am J Physiol Renal Physiol. 2013;305(6):F891–900. Epub 2013/07/26. doi: ajprenal.00149.2013 [pii] pmid:23884140; PubMed Central PMCID: PMC3761290.
- 19. Breyer MD, Bottinger E, Brosius FC 3rd, Coffman TM, Harris RC, Heilig CW, et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol. 2005;16(1):27–45. Epub 2004/11/26. doi: ASN.2004080648 [pii] pmid:15563560.
- 20. Brosius FC 3rd, Alpers CE, Bottinger EP, Breyer MD, Coffman TM, Gurley SB, et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol. 2009;20(12):2503–12. Epub 2009/09/05. doi: ASN.2009070721 [pii] pmid:19729434.
- 21. Li H, Tran VV, Hu Y, Mark Saltzman W, Barnstable CJ, Tombran-Tink J. A PEDF N-terminal peptide protects the retina from ischemic injury when delivered in PLGA nanospheres. Exp Eye Res. 2006;83(4):824–33. Epub 2006/07/11. doi: S0014-4835(06)00210-7 [pii] pmid:16822505.
- 22. You H, Gao T, Cooper TK, Morris SM Jr., Awad AS. Arginase inhibition mediates renal tissue protection in diabetic nephropathy by a nitric oxide synthase 3-dependent mechanism. Kidney Int. 2013;84(6):1189–97. Epub 2013/06/14. doi: ki2013215 [pii] pmid:23760286; PubMed Central PMCID: PMC3783645.
- 23. Awad AS, Kinsey GR, Khutsishvili K, Gao T, Bolton WK, Okusa MD. Monocyte/Macrophage Chemokine Receptor CCR2 Mediates Diabetic Renal Injury. Am J Physiol Renal Physiol. 2011. Epub 2011/09/02. doi: ajprenal.00332.2011 [pii] pmid:21880831.
- 24. Morris SM Jr., Gao T, Cooper TK, Kepka-Lenhart D, Awad AS. Arginase-2 mediates diabetic renal injury. Diabetes. 2011;60(11):3015–22. Epub 2011/09/20. [pii]. pmid:21926276; PubMed Central PMCID: PMC3198072.
- 25. You H, Gao T, Cooper TK, Brian Reeves W, Awad AS. Macrophages directly mediate diabetic renal injury. Am J Physiol Renal Physiol. 2013;305(12):F1719–27. Epub 2013/11/01. doi: ajprenal.00141.2013 [pii] pmid:24173355.
- 26. You H, Gao T, Cooper TK, Morris SM Jr., Awad AS. Arginase inhibition mediates renal tissue protection in diabetic nephropathy by a nitric oxide synthase 3-dependent mechanism. Kidney Int. 2013. Epub 2013/06/14. [pii]. pmid:23760286.
- 27. Morris SM Jr., Gao T, Cooper TK, Kepka-Lenhart D, Awad AS. Arginase-2 mediates diabetic renal injury. Diabetes. 60(11):3015–22. Epub 2011/09/20. doi: db11-0901 [pii] pmid:21926276.
- 28. Awad AS, Kinsey GR, Khutsishvili K, Gao T, Bolton WK, Okusa MD. Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury. Am J Physiol Renal Physiol. 301(6):F1358–66. Epub 2011/09/02. doi: ajprenal.00332.2011 [pii] pmid:21880831.
- 29. Kalantarinia K, Awad AS, Siragy HM. Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. Kidney Int. 2003;64(4):1208–13. pmid:12969138.
- 30. Awad AS, Huang L, Ye H, Duong ET, Bolton WK, Linden J, et al. Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy. Am J Physiol Renal Physiol. 2006;290(4):F828–37. pmid:16332931.
- 31. Wang JJ, Zhang SX, Lu K, Chen Y, Mott R, Sato S, et al. Decreased expression of pigment epithelium-derived factor is involved in the pathogenesis of diabetic nephropathy. Diabetes. 2005;54(1):243–50. Epub 2004/12/24. doi: 54/1/243 [pii]. pmid:15616035.
- 32. Tesch GH. Role of macrophages in complications of type 2 diabetes. Clin Exp Pharmacol Physiol. 2007;34(10):1016–9. Epub 2007/08/24. doi: CEP4729 [pii] pmid:17714088.
- 33. Nakamura T, Ebihara I, Fukui M, Osada S, Nagaoka I, Horikoshi S, et al. Messenger RNA expression for growth factors in glomeruli from focal glomerular sclerosis. Clin Immunol Immunopathol. 1993;66(1):33–42. Epub 1993/01/01. doi: S0090122983710056 [pii]. pmid:8095004.
- 34. Liu H, Ren JG, Cooper WL, Hawkins CE, Cowan MR, Tong PY. Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site. Proc Natl Acad Sci U S A. 2004;101(17):6605–10. Epub 2004/04/21. [pii]. pmid:15096582; PubMed Central PMCID: PMC404092.
- 35. Liu E, Morimoto M, Kitajima S, Koike T, Yu Y, Shiiki H, et al. Increased expression of vascular endothelial growth factor in kidney leads to progressive impairment of glomerular functions. J Am Soc Nephrol. 2007;18(7):2094–104. Epub 2007/06/08. doi: ASN.2006010075 [pii] pmid:17554151.
- 36. Veron D, Reidy KJ, Bertuccio C, Teichman J, Villegas G, Jimenez J, et al. Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease. Kidney Int. 2010;77(11):989–99. Epub 2010/04/09. doi: ki201064 [pii] pmid:20375978.
- 37. Veron D, Bertuccio CA, Marlier A, Reidy K, Garcia AM, Jimenez J, et al. Podocyte vascular endothelial growth factor (Vegf(1)(6)(4)) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes. Diabetologia. 2011;54(5):1227–41. Epub 2011/02/15. pmid:21318407; PubMed Central PMCID: PMC3397150.
- 38. Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int. 2006;69(12):2131–47. pmid:16688120.
- 39. Harris RC, Hoover RL, Jacobson HR, Badr KF. Evidence for glomerular actions of epidermal growth factor in the rat. J Clin Invest. 1988;82(3):1028–39. Epub 1988/09/01. pmid:3262122; PubMed Central PMCID: PMC303617.
- 40. Breyer MD, Redha R, Breyer JA. Segmental distribution of epidermal growth factor binding sites in rabbit nephron. Am J Physiol. 1990;259(4 Pt 2):F553–8. Epub 1990/10/01. pmid:2221092.
- 41. Zhang MZ, Wang Y, Paueksakon P, Harris RC. Epidermal growth factor receptor inhibition slows progression of diabetic nephropathy in association with a decrease in endoplasmic reticulum stress and an increase in autophagy. Diabetes. 2014;63(6):2063–72. Epub 2014/04/08. doi: db13-1279 [pii] pmid:24705402; PubMed Central PMCID: PMC4030104.